explore -WSS

explore

author：comprehensive 2025-10-03 00:38:31 - browse：7223

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Walensky prepares to leave CDC — and Congress — behind

Wikipedia

knowledge

WSS

Hollywood unions extend contract negotiations for actors

U.K. officials, researchers try to ease path for bespoke genetic treatments

Alkermes shareholders re

Adam's Take: Intra

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

The cancer drug shortage isn’t new — and neither are the solutions

Wikipedia

explore

focus

Medical records are filled with copy

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Apple is now the first public company to be valued at $3 trillion

Bring on the sabbaticals for nurses

Wildfire smoke exposes gaps in outdoor worker protections

Medicare details structure of new drug price negotiation program

United colonoscopy coverage change 'may cost lives,' doctors say

Mirador, a new biotech startup, launches with $400 million

Psychedelics group wrestles with new pharma identity

Medical devices makers are asking for forgiveness, not permission

entertainment

BioMarin wins approval for gene therapy to treat hemophilia A

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Bring on the sabbaticals for nurses

Pfizer, Moderna say biotech, pharma drug development is a sprint

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

knowledge

Wikipedia

knowledge

leisure time